C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

Overview
Date Founded

2015

Headquarters

490 Arsenal Way, Suite 200, Watertown, MA, 02472, USA

Type of Company

Public

Employees (Worldwide)

99

Industries

Biotechnology
Pharmaceuticals
IT Consulting & Services
Medical Support Services

Company Description

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at C4 Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

President, Chief Executive Officer & Director

Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer

Chief Legal Officer

Vice President of Business Development

Co-Founder

Chief People Officer

Senior Vice President-Communications

Paths to C4 Therapeutics, Inc.
Potential Connections via
Relationship Science
You
C4 Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Details Hidden

Cormorant Asset Management manages a hedge fund and a private equity fund that focus on investments in the healthcare sector. The firm employs a fundamental, research intensive approach that focuses on primary research to identify investment opportunities.The objective of the hedge fund is to generate superior risk-adjusted returns with low market correlation. Cormorant seeks to accomplish this objective primarily through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. The firm invests substantially, but not solely, in publicly traded equity securities in the healthcare and life science industries.The private equity fund’s investment objective is to generate significant long-term capital appreciation by creating or investing in market innovative companies in the biotechnology and life sciences marketplace. Cormorant expects to achieve this objective by primarily investing in “crossover” (or mezzanine) round or pre-IPO portfolio companies in the biotech, medical device, diagnostics, generics, pharmaceutical, specialty pharmaceutical and life science research tool sectors. Cormorant, may also invest in portfolio companies through PIPEs and in start-up portfolio companies, including start-ups organized, managed and funded with Cormorant’s or their affiliates’ proprietary capital.

Details Hidden

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges. The firm’s research process will be focused on a scientific approach to assessing and accurately defining the fundamental value of outcomes surrounding transformational events in the lifecycle of healthcare companies.

Recent Transactions
Details Hidden

C4 Therapeutics, Inc. issued USD Common Stock

Details Hidden

C4 Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onC4 Therapeutics, Inc. issued USD Common Stock

Escrow Agent

Advised onC4 Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onC4 Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onC4 Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onC4 Therapeutics, Inc. issued USD Common Stock

Attorney

Advised onC4 Therapeutics, Inc. issued USD Common Stock

Clients

Alphabet, Inc. is a holding company, which engages in the business of acquisition and operation of different companies. It operates through the Google and Other Bets segments. The Google segment includes its main Internet products such as ads, Android, Chrome, hardware, Google Cloud, Google Maps, Google Play, Search, and YouTube. The Other Bets segment consists of businesses such as Access, Calico, CapitalG, GV, Verily, Waymo, and X. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of 2020
Market Capitalization
$1.42B
Total Enterprise Value
$1.08B
Earnings Per Share
$-1.54
Revenue
$33.2M
Net Profit
$-66.3M
EBITDA
$-57.6M
EBITDAMargin
-173.54%
Total Debt
$22.9M
Total Equity
$281M
Enterprise Value / Sales
32.47x
TEVNet Income
-16.25x
Debt TEV
0.02x
Investors
Details Hidden

Bain Capital Life Sciences is an active manager which invests in companies located in across the globe. The firm follows of biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies. Bain Capital Life Sciences provides investments in the form of inflection capital, growth capital, fallen angels and larger private equity types.

Details Hidden

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Details Hidden

MSPI is an active manager which does not have industry limitations. It consider co-investments with other investors.

Competitors
Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by C4 Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of C4 Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and C4 Therapeutics, Inc..